<DOC>
	<DOCNO>NCT00118300</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray type radiation kill tumor cell . Internal radiation use radioactive material place directly near tumor kill tumor cell . Giving chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose capecitabine give together radiation therapy treat patient locally advanced cervical cancer pelvic cancer .</brief_summary>
	<brief_title>Capecitabine Radiation Therapy Treating Patients With Locally Advanced Cervical Cancer Other Pelvic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity capecitabine give combination pelvic external beam radiotherapy intracavitary brachytherapy patient primary recurrent locally advanced cervical cancer pelvic malignancy . Secondary - Determine clinical anti-tumor response patient treat regimen . - Determine adverse clinical sequela patient treat regimen . OUTLINE : This multicenter , dose-escalation study capecitabine . Patients undergo external beam radiotherapy whole pelvis daily 5 day week week 1-5 receive 1 2 application low-dose rate intracavitary brachytherapy week 7-8 OR 5 application high-dose rate ( HDR ) * intracavitary brachytherapy weekly week 4-8 . Patients also receive oral capecitabine twice daily 7 day week week 1-5 7-8 . Courses repeat every 12 week absence disease progression unacceptable toxicity . NOTE : *No external beam radiotherapy administer day HDR brachytherapy . If majority external beam radiotherapy administer , HDR brachytherapy may administer 2 application per week ( separate least 72 hour ) order complete treatment week 8 . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A minimum 6 patient treated MTD . After completion study treatment , patient follow 1 month , every 3 month 1 year , every 6 month 2 year , annually 2 year . PROJECTED ACCRUAL : Approximately 4-24 patient accrue study within 2-12 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cervical cancer pelvic malignancy , include vaginal , endometrial , ovarian cancer Primary recurrent disease Locally advance disease , define follow : Stage IB2IVA ( cervical vaginal cancer ) Any nonextra pelvic metastatic stage ( endometrial ovarian cancer ) Not amenable curative surgical resection alone Bidimensionally measurable clinically evaluable disease Refused ineligible weekly IV cisplatin chemotherapy due renal insufficiency , prior platinum adverse sensitivity , preexist neuropathy , concurrent comorbid illness No histologically confirm clinically suspicious ( ≥ 1 cm ) paraaortic lymphadenopathy No brain metastasis primary brain tumor PATIENT CHARACTERISTICS : Age 18 ( 80 second third doseescalation level ) Performance status GOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Hepatic Bilirubin ≤ 1.5 mg/dL AST ALT &lt; 2 time upper limit normal Renal See Disease Characteristics Creatinine normal OR Creatinine clearance ≥ 30 mL/min* No proteinuria clinically significant impaired renal function NOTE : *Creatine clearance testing require patient &gt; 60 year age Cardiovascular No symptomatic New York Heart Association class III IV congestive heart failure No unstable angina pectoris No cardiac arrhythmia No uncontrolled hypertension Gastrointestinal Able swallow oral medication No bowel obstruction No malabsorption illness Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity capecitabine fluorouracil No ongoing active infection No uncontrolled illness No psychiatric illness social situation would preclude study compliance No active invasive malignancy Prior malignancy remission ≥ 6 month currently treat allow PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Recovered prior chemotherapy At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) Prior chemotherapy nongynecologic malignancy adjuvant set allow No prior capecitabine Endocrine therapy Prior adjuvant hormonal therapy allow Radiotherapy Recovered prior radiotherapy At least 4 week since prior radiotherapy Prior radiotherapy nongynecologic malignancy allow No prior low abdominal pelvic radiotherapy Surgery Not specify Other At least 3 week since prior investigational anticancer agent recover No prior anticancer treatment contraindicates study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage II vaginal cancer</keyword>
	<keyword>stage I vaginal cancer</keyword>
</DOC>